High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma

TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials

(2016) Dae-Won Lee et al.   BRITISH JOURNAL OF CANCER

Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling

(2016) Feng Liu et al.   Scientific Reports

High Serum Transforming Growth Factor- 1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib

(2015) T.-H. Lin et al.   CLINICAL CANCER RESEARCH

Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib

(2015) Takeshi Terashima et al.   HEPATOLOGY RESEARCH

The Relationship Between Serum Interleukin-6 and the Recurrence of Hepatitis B Virus Related Hepatocellular Carcinoma after Curative Resection

(2015) Tao Sheng et al.   MEDICINE

Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?

(2015) Yu-Yun Shao   WORLD JOURNAL OF GASTROENTEROLOGY

Tumor-Associated Macrophages Produce Interleukin 6 and Signal via STAT3 to Promote Expansion of Human Hepatocellular Carcinoma Stem Cells

(2014) Shanshan Wan et al.   GASTROENTEROLOGY

Predictive Biomarkers of Antiangiogenic Therapy for Advanced Hepatocellular Carcinoma: Where Are We?

(2013) Yu-Yun Shao et al.   Liver Cancer

Interleukin-6 signaling pathway in targeted therapy for cancer

(2012) Yuqi Guo et al.   CANCER TREATMENT REVIEWS

Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy

(2012) Y.-Y. Shao et al.   CLINICAL CANCER RESEARCH

Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma

(2012) J. M. Llovet et al.   CLINICAL CANCER RESEARCH

Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma

(2012) Jeong Won Jang et al.   CYTOKINE

Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma

(2012) Yu-Yun Shao et al.   ONCOLOGY

Preoperative Levels of Serum Interleukin-6 in Patients with Hepatocellular Carcinoma

(2011) Xiong-Hao Pang et al.   HEPATO-GASTROENTEROLOGY

Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma

(2011) Koji Miyahara et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma

(2010) Chih-Hung Hsu et al.   JOURNAL OF HEPATOLOGY

The Interleukin-8 Pathway in Cancer

(2008) D. J.J. Waugh et al.   CLINICAL CANCER RESEARCH

Hepatocellular carcinoma development requires hepatic stem cells with altered transforming growth factor and interleukin-6 signaling

(2008) Nicholas A. Shackel et al.   HEPATOLOGY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE